Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Dianthus Therapeutics, Inc. before investing.

In this article, we go over a few key elements for understanding Dianthus Therapeutics, Inc.’s stock price such as:

• Dianthus Therapeutics, Inc.’s current stock price and volume
• Why Dianthus Therapeutics, Inc.’s stock price changed recently
• Upgrades and downgrades for DNTH from analysts
• DNTH’s stock price momentum as measured by its relative strength

About Dianthus Therapeutics, Inc. (DNTH)

Before we jump into Dianthus Therapeutics, Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.

Want to learn more about Dianthus Therapeutics, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Dianthus Therapeutics, Inc..

Dianthus Therapeutics, Inc.’s Stock Price as of Market Close

As of July 31, 2026, 4:00 PM, CST, Dianthus Therapeutics, Inc.’s stock price was $106.920.

Dianthus Therapeutics, Inc. is down 5.08% from its previous closing price of $112.640.

During the last market session, Dianthus Therapeutics, Inc.’s stock traded between $105.660 and $114.550. Currently, there are approximately 48.03 million shares outstanding for Dianthus Therapeutics, Inc..

Dianthus Therapeutics, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Dianthus Therapeutics, Inc. Stock Price History

Dianthus Therapeutics, Inc.’s (DNTH) price is currently up 9.68% so far this month.

During the month of July, Dianthus Therapeutics, Inc.’s stock price has reached a high of $114.550 and a low of $87.400.

Over the last year, Dianthus Therapeutics, Inc. has hit prices as high as $114.550 and as low as $18.080. Year to date, Dianthus Therapeutics, Inc.’s stock is up 159.45%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Dianthus Therapeutics, Inc. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of July 31, 2026, there was 1 analyst who downgraded Dianthus Therapeutics, Inc.’s stock and 2 analysts who upgraded over the last month.

Additionally, you'll want to evaluate Dianthus Therapeutics, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Dianthus Therapeutics, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Dianthus Therapeutics, Inc. (DNTH) by visiting AAII Stock Evaluator.

Relative Price Strength of Dianthus Therapeutics, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of July 31, 2026, Dianthus Therapeutics, Inc. has a weighted four-quarter relative price strength of 40.10%, which translates to a Momentum Score of 98 and is considered to be Very Strong.

Want to learn more about how Dianthus Therapeutics, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Dianthus Therapeutics, Inc. Stock Price: Bottom Line

As of July 31, 2026, Dianthus Therapeutics, Inc.’s stock price is $106.920, which is down 5.08% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Dianthus Therapeutics, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.